国产精品有码-国产精品揄-国产精品揄拍一区二区-国产精品原创不卡在线-国产精品原创在线网址-国产精品再线线观看

GFH925 Receives Breakthrough Designation as Monotherapy for Previously Treated Advanced Colorectal Carcinoma

May 15, 2023
Share

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI351 (GFH925) for the treatment of previously treated advanced colorectal carcinoma (CRC) patients with KRASG12C mutation.

This BTD for GFH925 was based on the pooled analysis of two ongoing clinical trials (NCT05005234, NCT05497336), which include 54 CRC patients that received GFH925 monotherapy. Favorable safety and tolerability and promising antitumor activity of GFH925 monotherapy were observed. The study results will be published at the upcoming American Society Of Clinical Oncology (ASCO) Annual Meeting 2023.

GFH925 is the first KRASG12C inhibitor that received NMPA BTD for advanced CRC.  In January 2023, GFH925 has received NMPA BTD for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation who have received at least one systemic therapy.  

NMPA Breakthrough Therapy Designation is intended to facilitate and expedite the development and review of an investigational drug to treat a serious disease or condition when preliminary clinical evidence indicates that the drug has demonstrated substantial improvement over current therapies. The BTD will not only qualify a drug candidate to receive status for rapid review by the CDE, but it will also allow the sponsor to obtain timely advice and communication from the CDE to accelerate the approval and launch to address the unmet clinical need of patients at an accelerated pace.

About GFH925(IBI351) 

Discovered by GenFleet Therapeutics, GFH925 is a novel, orally active, potent KRASG12C inhibitor designed to effectively target the GTP/GDP exchange, an essential step in pathway activation, by modifying the cysteine residue of  KRASG12C protein covalently and irreversibly. Preclinical cysteine selectivity studies demonstrated high selectivity of GFH925 towards KRASG12C. Subsequently, GFH925 effectively inhibits the downstream signal pathway to induce tumor cells’apoptosis and cell cycle arrest. In September 2021, Innovent and GenFleet entered into an exclusive license agreement for the development and commercialization of GFH925 in China (including the Chinese mainland, Hong Kong, Macau and Taiwan) with additional option-in rights for global development and commercialization.

主站蜘蛛池模板: 日韩A级午夜大黄片 | 视频在线观看一区 | 亚洲无码AV1区二区 亚洲无码AV一二三区 | 99精品成人无码A片观看金桔 | 日本女优天堂网页 | 国产精品三级在 | vr国产亚洲欧美在线 | 国产网站久章草在线视频 | 国产精品国产精品国产专区不卡 | 午夜美女国产一区 | 中文无码区a∨视频 | 91桃色在线网站免费 | 91丨九色丨丰满熟女 | 人人影视免费电影在线观看手机版 | 日韩一区国产二 | 午夜亚洲理论片在线观看 | 日韩一区不卡 | 亚洲av永久精品无码 | 国内高清无码一二三区 | 亚洲成人世界 | 日韩精品一区二 | 欧美日韩欧 | 91天堂国产在线在线 | 国产饥渴熟女91专区 | 欧美日本在| 日韩剧在线观看免费全集 | 香蕉网久久| 国产精品蜜桃 | 国产麻豆一精品一av一免费软件 | 国产99成人秘 入口 国产99精品 | 国产丰满大乳无码免费播放 | 国产浪潮午夜精品在线 | 日韩av免费观看中文字幕 | 粉嫩Aⅴ一区 | 69精品国产人妻国产毛片 | 欧美精品免费专区 | 欧美日韩国产剧情 | 国产一区在线不 | 亚洲欧美日本a∨天堂 | 午夜射精日韩 | 欧美男同|